Stockscreener 앱 받기
0.9677
2.41%
-0.0239
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics outlines strategic rationale for proposal to change jurisdiction - Yahoo Finance
Stocks in play: Oncolytics Biotech Inc. - Barchart.com
Oncolytics Biotech plans to shift incorporation from Canada to Nevada - Investing.com
Oncolytics (ONCY) Plans to Shift Incorporation to Nevada for Str - GuruFocus
Oncolytics Biotech plans to shift incorporation from Canada to Nevada By Investing.com - Investing.com South Africa
Oncolytics Biotech Seeks Nevada Domestication to Align with U.S. Growth Strategy - TipRanks
Oncolytics Biotech Inc. Proposes Change of Jurisdiction to Nevada to Enhance U.S. Focus and Strategic Growth - Quiver Quantitative
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada - The Spec
Oncolytics Biotech Inc. - Menafn.com
Is Oncolytics Biotech Inc. stock a contrarian buyInsider Buying & Technical Analysis for Trade Confirmation - ulpravda.ru
Oncolytics Biotech files patent application to extend pelareorep protection By Investing.com - Investing.com Australia
Is Oncolytics Biotech Inc. stock a buy for dividend growth - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - The Manila Times
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings - PharmiWeb.com
Oncolytics Biotech®? Provides Update on Intellectual Property Strategy and Patent Filings - MarketScreener
Why Oncolytics Biotech Inc. stock is rated strong buy2025 Valuation Update & Daily Profit Maximizing Trade Tips - ulpravda.ru
Oncolytics Biotech Moves to Extend Pelareorep Patent Runway Beyond 2044 - TipRanks
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - Investing News Network
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech expands GI cancer advisory board with three experts By Investing.com - Investing.com Nigeria
Oncolytics Biotech Adds Leading GI Oncologists to Advisory Board as It Prepares Pivotal Pelareorep Trials - TipRanks
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris - Business Wire
Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail
What drives Oncolytics Biotech Inc stock priceStock Rotation Strategies & Big Profit Small Investment - earlytimes.in
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Shares Down 1.5%Here's Why - MarketBeat
Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting - ACCESS Newswire
Revenue per share of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView — Track All Markets
What hedge fund activity signals for Oncolytics Biotech Inc. stockWeekly Profit Recap & Technical Pattern Based Signals - Улправда
Why Oncolytics Biotech Inc. stock is recommended by analystsMarket Growth Report & Real-Time Buy Signal Notifications - Улправда
Published on: 2025-12-20 04:27:06 - Улправда
Will Oncolytics Biotech Inc. stock sustain high P E ratiosMarket Activity Summary & Consistent Return Strategy Ideas - DonanımHaber
Is Oncolytics Biotech Inc. stock trading near support levelsCPI Data & AI Enhanced Trading Signals - DonanımHaber
What analyst consensus says on Oncolytics Biotech Inc. stockJuly 2025 Retail & Reliable Entry Point Trade Alerts - Улправда
Published on: 2025-12-18 16:49:38 - Улправда
Lake Street Remains a Buy on Oncolytics Biotech (ONCY) - The Globe and Mail
[6-K] ONCOLYTICS BIOTECH INC Current Report (Foreign Issuer) | ONCY SEC FilingForm 6-K - Stock Titan
Oncolytics eyes controlled study for pelareorep in colorectal cancer - The Pharma Letter
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer - BioSpace
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Cantech Letter
Oncolytics Says Pelareorep Shows 33% Response Rate in Colorectal Cancer Patients; Shares Rise - marketscreener.com
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Oncolytics rises on additional data for pelareorep in colorectal cancer - Seeking Alpha
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer - Investing.com India
0.90%
자본화:
|
볼륨(24시간):